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«Aspetti nutrizionali nei pazienti affetti da IBD: quali prospettive?»
Summary. Inflammatory bowel disease (IBD) is a chronic disorder characterized by a relapsing-remitting 
course, which alternates between active and quiescent states, ultimately impairing a patients’ quality of life. 
The two main types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). In physiological conditions 
the gut is costantly exposed to various antigens, commensal microflora and pathogens and the inflammatory 
response is finely balanced. It is thought that a vast number of environmental risk factors may be implicated 
in the development of IBD, including smoking, dietary factors, psychological stress, use of non-steroidal anti-
inflammatory drugs and oral contraceptives, appendectomy, breastfeeding, as well as infections. Nutritional 
support, as a primary therapy, has a crucial role in the management of patients with IBD. The gut microbiota 
is clearly manipulated by dietary components such as n-3 polyunsaturated fatty acids (n-3 PUFA) and coniu-
gated linoleic acid (CLA) which favorably reduce endotoxin load via shifts in the composition and metabolic 
activity of the microbial community. In particular, the beneficial effect of n-3 PUFAs and fermentable fiber, 
during the remission/quiescent phase of both CD and UC is highlighted. In fact, PUFAs are associated with 
a less grade of inflammation since they are metabolized to 3-series prostaglandins and thromboxanes and 
5-series leukotrienes and, in addition, exert antiinflammatory effects when compared with their n-6 PUFA 
counterparts. In similar action to dietary n-3 PUFA, coniugated linoleic acid (CLA) have been reported to 
ameliorate intestinal inflammation in animal models of IBD. Currently is still unclear the role of the fibers 
in  helping the remission of the disease. Data about the consumption of fiber are controversial. On one hand, 
dietary fibers can act as effective prebiotics by altering the intestinal microbial composition and promoting the 
growth of beneficial bacterial communities within the large intestine.  On the other hand,  fibers can promote 
diarrhea, pain and gas aggravating the clinical state. We suggest that the consumption of fermentable fibers 
may have a good impact on patients’ health. 
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Riassunto. Le Malattie infi ammatorie croniche intestinali (IBD) rappresentano delle patologie infi ammato-
rie croniche a carattere ricorrente. I principali tipi di IBD sono il Morbo di Crohn e la Rettocolite Ulcerosa. 
In condizioni fisiologiche nell’intestino la microflora endogena, gli antigeni patogeni e la risposta infiamma-
toria di base sono mutualmente bilanciati. Un vasto numero e tipologia di fattori ambientali sono implicate 
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Introduction
IBD is an acronym that indicate a set of chronic 
recurrent disorders characterised by an excessive and 
prolonged intestinal inflammation. This group of dis-
eases has been classified considering: location, severity 
and extent of the bowel involvement. The two main 
types of IBD are Crohn’s disease (CD) and ulcerative 
colitis (UC). CD shows a transmural granulomatous 
inflammation that can involve any segment of the in-
testine affecting all layers of the intestinal wall while 
UC is limited to the mucosa and superficial submucosa 
of the colon (1).
It is well established that a microflora imbalance 
is present in both leading to a modification of intercel-
lular tight junctions responsible of mucosal permeabil-
ity. As a consequence various antigens can penetrate 
within the intercellular space causing the activation of 
MALT and tissue damage.
In physiological conditions the gut is costantly 
exposed to various antigens, commensal microflora 
and pathogens and the inflammatory response is finely 
balanced (2). Anyhow in some individuals with genet-
ic susceptibility an anomalous inflammatory response 
can arise due to the deregulation of the negative feed-
back mechanisms implicated in its self-regulation.
Recent data demonstrate that some single nucleo-
tide polymorphisms can be associated with IBD. These 
mutations alter the expression of genes implicated in 
bacterial recognition, immune response and mucosal 
transport or polarity. It has been recognized that af-
fected patients are more sensitive to bacterial invasion 
as they had lower levels of defensin gene expression in 
Paneth cells.
Generally, the aberrant inflammatory state causes 
an extensive tissue injury followed by edema, decreased 
mucous production, crypt cell hyperplasia, erosions 
and ulcerations. The function of the epithelial barrier 
appears impaired and the transmission of extracellular 
signals to the membrane is compromised.
Several studies suggest that nutrition may play 
an important role in the pathogenesis of the disease 
and may also modulate the intestinal inflammatory re-
sponse showing a therapeutic effect (3).
This review is devoted to underlying the role of 
the diet and its potential benefits on the health of pa-
tients affected of moderate and mild forms of IBD.
a vario titolo nella insorgenza delle IBD; tra questi ricordiamo il fumo di sigaretta, i fattori dietetici, lo stress 
psicologico, l’uso di farmaci antinfiammatori non steroidei, i contraccettivi, l’appendicetmia, l’allattamento al 
seno e le infezioni. Il support nutrizionale, unitamente alla terapia, ha un ruolo cruciale nel management delle 
IBD. Il microbiota intestinale è strettamente regolato da componenti introdotti con la dieta come gli acidi 
grassi polinsaturi, l’acido linoleico, che favoriscono la riduzione delle endotossine e regolano la attività meta-
bolica della comunità microbica intestinale. Nello specifico, gli acidi grassi polinsaturi e le fibre fermentabili 
hanno un ruolo peculiare durante le fasi di remissione/quiescenza di malattia. Gli acidi grassi polinsaturi 
sono associati ad un basso grado di infiammazione mucosale. Queste caratteristiche sono state ampiamente 
evidenziate negli animali di laboratorio in cui è stata indotta la IBD. Quindi, una dieta ricca di acidi grassi 
polinsaturi ha evidenziato un miglioramento del quadro infiammatorio intestinale. Ad oggi, non conosciamo 
bene i specifici meccanismi biomolecolari antinfiammatori che le fibre esplicano sulla mucosa intestinale e 
che inducono la fase di remissione. Le fibre introdotte con la dieta esplicano una fattiva azione pre-biotica che 
promuove la crescita di una corretta flora microbica. In conclusion, fibre hanno una azione antinfiammatoria 
nei pazienti affetti da IBD con un miglioramento della storia clinica di malattia.
Parole chiave:  malattie infiammatorie croniche intestinali, IBD, nutrizione, acidi grassi a catena corta, mi-
crobiota, disbiosi.
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Aetiologic and pathogenetic mechanisms of IBD
There is no single, established cause for these pa-
thologies. The most widely accepted working hypoth-
esis is that IBD represents a dysregulated immune re-
sponse to common intraluminal antigens. It has been 
established a crucial pathophysiologic role for enteric 
bacteria. The onset of inflammation can be associated 
with a dysbalanced bacterial flora, with a pre-domi-
nance of certain  harmful species or bacterial metabolic 
products and an insufficient concentration of protec-
tive commensal species (4).
The etiopathogenesis of inflammatory bowel dis-
eases (IBDs) is multifactorial and therefore cannot be 
explained only in terms of genetic susceptibility (5).
A vast number of environmental risk factors may 
influence the development of IBD, including smoking, 
dietary factors, psychological stress, use of non-steroi-
dal anti-inflammatory drugs and oral contraceptives, 
appendectomy, breastfeeding, as well as infections .
We focus on diet as it can influence the species 
composition of the intestinal microbiota (6, 7).
Pre-illness diet could be a significant risk factor 
for the pathogenesis of IBD.
Recent analysis underline associations between 
IBD development and consumption of fiber, fruits 
or vegetables. Some authors demonstrated that the 
risk of CD is inversely associated with the intake of 
fruits and vegetables in a pediatric cohort and in a 
larger prospective adult study (8). Moreover, it seems 
that the higher intake of animal protein is also prob-
ably linked to the increased risk of CD. Western diet, 
characterized by high amount of sucrose, refined car-
bohydrate and omega-6 fatty acids and poor intake of 
fruits and vegetables, is therefore considered a trigger 
for this type of disorders. Recent evidences highlight 
also that foods are contaminated by natural contami-
nants such as  dust and additives which may be an-
tigenic (9, 10). Correlations studies from the Japa-
nese area demonstrate an increasing incidence of CD 
within the population due to the progressive changes 
in diet habits associated with a massive amount of 
animal fat especially v-6 polyunsaturated fatty acids 
(PUFAs) (11, 12).
Nutrition therapeutic approaches: dietary interven-
tions
Undernutrition has been often reported in pa-
tients with inflammatory bowel disease (IBD), par-
ticularly in patients with active Crohn’s disease. The 
mechanisms standing behind malnutrition include re-
duced oral intake, increased energy requirements due 
to systemic inflammation, poor digestion, malabsorp-
tion due to chronic inflammation, and (mainly in CD 
patients) previous surgical resection or bypass of the 
bowel and protein-dispersion (13).
Factors that contribute to decreased food intake, 
in particular, include loss of appetite, hunger and de-
pressed mood (14).
It is important to distinguish the difference be-
tween nutrition, requirements likely to prevent or delay 
development or early progression of the disease from 
secondary effects associated with late stage complica-
tions of IBD, especially malnutrition (15).
In quiescent IBD energy and substrate metabo-
lism is normal or shows the typical changes of a short-
age of energy intake with a decrease in carbohydrate 
and an increase in fat oxidation. During the active 
phase patients develop a mixed picture of an inflam-
matory reaction and malnutrition with slight increases 
in energy expenditure and a relative increase in fat oxi-
dation and decrease in carbohydrate oxidation. These 
changes are, however, quickly reversible when patients 
are given nutritional support (16).
Nutritional support is adequate as disease modi-
fying therapy for growth failure in children or adoles-
cents with active small bowel disease (grade A). It may 
be used in preference to steroids, immunomodulators, 
or surgery for any patient with active disease (grade B), 
or for those unresponsive to mesalazine or in whom 
corticosteroids are contraindicated (grade C).
It can be considered as adjunctive therapy for any 
malnourished patients (grade C), or for those who have 
difficulty maintaining normal nutritional status (grade C).
Nutritional support is also appropriate for those 
with intestinal partial obstruction awaiting surgery 
(grade C), or severely symptomatic perianal disease 
(grade C), or those with postoperative complications. 
Enteral nutrition is preferred when the patient’s con-
dition permits (grade C).
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Serum vitamin B12 is best measured annually in 
patients with ileal CD (grade C) (17)
Malabsorption rather than dietary insufficiency is 
the likely main underlying mechanism leading to fat-
soluble vitamin deficiencies which, in turn, can be as-
sociated with metabolic bone disorder (13).
A wide array of vitamin and mineral deficiencies 
occurs in inflammatory bowel disease, with varying de-
grees of clinical significance (18).
The most striking feature is the identification of 
a low serum folate level and, to a lesser extent, a low 
serum vitamin B12 level.
Other nutritional deficiencies that can be found 
are iron, zinc and selenium.
Zinc, in particular, is crucial in patients with 
Crohn’s disease presenting persistent fistulas because 
it play an essential role in wound healing. Moreover, it 
may be protective against free radical-mediated cellular 
damage since it is a co-factor for superoxide dismutase.
Nutrition has an important role in the manage-
ment of patients with IBD. It is able to correct macro 
and micronutrient deficiencies in malnourished indi-
viduals, reverse the physiopathological consequences 
of such deficiencies, exerte an anti-inflammatory 
therapeutic effect. The possibility of using a nutritional 
approach as primary treatment of IBD allow the aboli-
tion of the use of corticosteroids and other immuno-
modulating drugs, none of which are free from sys-
temic haematologic, metabolic and/or nutritional side 
effects (19-25).
It is thought that dietary products may modu-
late intestinal inflammation through: direct antigenic 
effect, alteration of gene expression, regulation of in-
flammatory mediators (e.g. eicosanoids), changes in 
the composition of the enteric flora and effects on gut 
permeability.
For example, the gut microbiota may be manipu-
lated by dietary components such as n-3 PUFA and 
coniugated linoleic acid (CLA) to favorably influence 
inflammatory disease risk by reducing endotoxin load 
via shifts in the composition and metabolic activity of 
the microbial community (8).
It seems that PUFA may ameliorate disease sever-
ity by activating one or several PPAR isoforms in the 
gut. An evident accelerated regeneration of intestinal 
epithelia is observed when this receptor is activated.
Different studies have shown that when consumed 
in sufficient quantities dietary fish oil results in de-
creased leukocyte chemotaxis, decreased production of 
reactive oxygen species and proinflammatory cytokines, 
and decreased adhesion molecule expression (26).
Several randomized, placebo-controlled, double-
blind studies analyze the role of fish oil in inflamma-
tory bowel disease. These trials indicate that fish oil is 
linked to a better clinical score, improved gut mucosal 
histology, improved sigmoidoscopic score, lower rate 
of relapse and decreased use of corticosteroids (27).
In recent years, special attention has been paid to 
fat and the lipid components of the diet as triggers of 
IBD. The discussion is focused mainly on the impor-
tance of essential fatty acids, in particular the relation 
between the fatty acids omega 3 and omega 6, where 
omega 6 activates inflammation while omega 3 restrain 
the inflammation, has been resumed (28).
This balance is better maintained if the consump-
tion of grain and oils saturated by omega 6 acids is 
reduced and that of fat fish, nuts, seeds and vegetables 
is increased (29).
It is advisable that patients follow an healthy and 
varied diet.
Recently it has been established that Mediteranne-
an diet, characterized by high levels of vegetables, fruits, 
olive oil, fish, grains, and nuts (30), was inversely as-
sociated with CD in both genders. Encouraging uptake 
of a Mediterannean diet may be desirable in protecting 
against IBD and other forms of chronic disease (8).
During acute phase of IBD prescribing a low-res-
idue diet, poor in insoluble fiber, may be recommended 
particularly in individuals with stricturing CD or se-
vere UC attacks.
The beneficial effect of n-3 polyunsaturated fatty 
acids (PUFAs) and fermentable fiber, during the re-
mission/quiescent phase of both CD and UC was 
highlighted. PUFAs are associated with a less   grade 
of inflammation since they are metabolized to 3-series 
prostaglandins and thromboxanes and 5-series leukot-
rienes and, in addition, exert antiinflammatory effects 
when compared with their n-6 PUFA counterparts (31).
Fermentable fiber generates much less residue 
than insoluble fiber, and it is fermented by colonic 
microflora, generating short chain fatty acids (SCFA), 
mainly butyrate, than can be of benefit in IBD. In 
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fact, there are in vitro-evidences suggesting that bu-
tyrate is able to down-regulate the production of pro-
inflammatory cytokines, to promote the restoration of 
intracellular Reactive Oxygen Specie (ROS) balance, 
and the activation of NF-kB. Moreover, according to 
several in vivo-studies, rectal administration of butyr-
ate or mixtures of SCFA were reported to decrease 
inflammation in patients with active UC. In similar 
action to dietary SCFA, coniugated linoleic acid  have 
been reported to ameliorate intestinal inflammation in 
animal models of IBD. In contrast to corticosteroids, 
CLA suppresses gut inflammatory responses while 
enhancing antigen specific responsiveness of T cells 
against viral and bacterial pathogens. A significant 
study demonstrate that pig with colonic lesions treated 
with diets supplemented with soybean oil, conjugat-
ed linoleic acid, fish oil or CLA and fish oil exhibit a 
beneficial effect of CLA in both disease severity and 
kinetics of appearance of clinical signs, whereas n-3 
PUFA failed to protect from the disorder but favored 
remission (32).
Available data  about nutritional interventions do 
not always match due to the incomplete knowledge 
of pathogenic mechanisms underlying IBD develop-
ment. Further studies are therefore needed to improve 
nutritional therapeutic approach.
Current evidences suggest that the use of prebiot-
ics can be positive in the treatment of IBD.
Prebiotics are non-digestible food ingredients 
that stimulate the growth and/or activity of bacteria 
in the digestive system confering benefits upon host 
wellbeing and health . Nowadays, only two dietary oli-
gosaccharides meet the criteria for prebiotic classifica-
tion: inulin and oligofructose, which are natural food 
ingredients or dietary fibers present in certain plants as 
storage carbohydrates. Many other food components 
have been shown to have prebiotic activity even though 
they do not fulfill the required criteria: (a) resistance 
to gastric acidity, hydrolysis by mammalian enzymes 
and absorption in the upper part of the gastrointes-
tinal tract; (b) fermentation by beneficial bacteria in 
the intestine; and (c) selective stimulation of growth 
and/or activity of colonic microflora toward a healthier 
composition (33).
Prebiotics and fiber carbohydrates are involved 
in different protective mechanisms such as increasing 
amount of short chain fatty acids (SCFAs), changes in 
the intestinal microbiota, improvement of the intesti-
nal barrier and regulation of the mucosal and systemic 
immune response. Dietary prebiotics can be applied 
to the prevention of human enteric inflammatory dis-
orders while maintaining optimal levels of immune 
surveillance. Recent studies showed how prebiotics in-
creased the number of beneficial bacteria such as lacto-
bacilli and bifidobacteria, while decreasing the disease-
causing bacteria in both animal models and human 
clinical studies (42, 44). Moreover, prebiotics can also 
provide resistance to colonization by pathogenic bac-
teria by inhibiting the adherence of pathogens to the 
gut epithelium (34).
The oral intake of probiotics and synbiotics is im-
portant because they are able to prevent an injury of 
the mucosa associated with the consumption of dairy 
products and species of grain containing gluten. Pro-
biotics yoghurt, bread enriched with fibre and B-vita-
mins and breakfast cereals  are good nutritional prod-
ucts with anti-inflammatory effects (28, 35-37).
Maintenance of remission: dietary modification
Prevention of relapse either of the disease or of a 
malnourished state is an important area of nutritional 
research. There is a lack of a safe, long-lasting modality 
for relapse prevention.  Exclusion diets are of use par-
ticularly for maintenance of remission. Despite early 
ideas about the involvement of sugars in the etiology 
of CD, the omission of sugar has not been found to 
be of benefit. Omega oil has shown promising results, 
particularly in reducing inflammation in UC, and to a 
lesser degree, in CD (38, 42).
“Elimination” involves remission induced by el-
emental feeds, followed by careful and slow ‘reintro-
duction’ of single food types to enable identification 
of those that precipitate symptoms. An alternative is 
the low-fibre, fat-limited exclusion (LOFFLEX) rein-
troduction diet, which involves a faster reintroduction 
phase of varied food types, instead of single food types, 
after EN-induced remission.
A food reintroduction diet can be used to iden-
tify any foods that may induce symptoms or cause 
problems. Examples of food reintroduction diets in-
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clude general elimination diets, and the LOFFLEX 
diet (LOw Fibre, Fat Limited, Exclusion diet) which 
excludes foods high in fat and fibre, before slowly 
reintroducing them. Initially a diet of bland foods is 
prescribed to the patient and subsequently foods are 
introduced in large quantities so that if there is a reac-
tion it becomes obvious (13).
Another alternative is known as the “FODMAP” 
diet. FODMAP is an abbreviation for a group of mol-
ecules found in food called fermentable carbohydrates. 
The initials stand for ‘Fermentable Oligosaccharides, 
Disaccharides, Monosaccharides and Polyols’. These 
molecules are not opportunely digested, so they pass 
into the colon acting as a food source for bacteria. The 
bacteria digest the FODMAPs and in doing so can 
cause symptoms such as bloating and wind (39).
Cutting out food containing FODMAPs is thought 
to alleviate these symptoms. Examples of FODMAP-
containing foods include fructose (apples, pears, corn 
syrup), lactose (dairy products, soft cheeses), fructans 
and galactans (wheat, cabbage, broccoli, watermelon) 
and polyols (apples, apricots, cauliflower, sorbitol).
Now is still unclear whether dietary exclusion–re-
introduction diets or FODMAP diets maintain remis-
sion through persistence of mucosal healing or are of 
predominant symptomatic benefit by alleviating ‘func-
tional’ symptoms. Probably FODMAP diets reduce 
the osmotic load and bacterial fermentation associated 
with the food delivered (40, 41), rather than having a 
primary anti-inflammatory effect.  
Conclusions
Crohn’s disease (CD) and ulcerative colitis (UC) 
show the presence of a condition of persistent  phlogo-
sis of the  intestinal mucosa. These diseases have com-
mon pathogenetic and epidemiological characteristics 
but, at the same time, have some specific aspects sug-
gesting that they must be considered  different clinical 
entities.  These disorders occur with latency periods 
alternated with periods of exacerbation.
The high consumption of refined carbohydrates, 
mainly sugar, in patients who experienced IBD may 
be one  risk factor. This association would explain the 
high incidence in industrialized countries.
It has been hypothesized that the increasing in-
cidence of IBD is linked to social and economic de-
velopment and alteration of lifestyle on the Western 
model (dietary changes, smoking, use of oral contra-
ceptives and stress).
A diet characterized by high amounts of sucrose, 
refined carbohydrates, fatty acids omega-6 (known as 
potential phlogogenic-oil sunflower seeds, soy, corn, 
nuts, and some margarines), few fruits and vegetables, 
compared to those who had greater consumption of 
fruits, vegetables and complex carbohydrates seems 
to be related to the development of these disorders . 
It was also suggested that the “urban diet” contain-
ing contaminants in food, such as dust, inorganic mi-
croparticles, additives, heavy metals which, combined 
with some components in the intestinal lumen favors 
the formation of particles capable of damaging the in-
testinal mucosa and to pass into the systemic circula-
tion.
The food, acting as luminal antigen, has been 
considered one of the causal factors in the immuno-
pathogenesis of the disease but it is unclear whether 
the antibodies against the food is the primary cause of 
the disease or whether they do not develop secondarily 
to the state of intestinal inflammation. Malnutrition is 
often present in these patients and numerous interven-
tions are often used.
Attention to nutrition-related issues must be 
considered central to the management of patients with 
inflammatory bowel disease. The use of nutrition as 
primary treatment in inflammatory bowel disease can 
have great importance, both in the onset of the disease 
and  in the duration of periods of remission.
Proper nutrition helps the body and to better tol-
erate the therapies that are made by reducing the side 
effects and giving the opportunity to the patient to re-
main in good health.
Currently is still unclear the role of the fiber in 
helping the remission of the disease. Data about the 
consumption of fibre are controversial. On one hand, 
dietary fibers can act as effective prebiotics by altering 
the intestinal microbial composition and promoting 
the growth of beneficial bacterial communities within 
the large intestine.   
Some authors reported a positive effect associated 
with the production by colonic microflora of short 
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chain fatty acids (SCFA), able to down-regulate the 
production of pro-inflammatory cytokines, to promote 
the restoration of intracellular Reactive Oxygen Specie 
(ROS) balance, and the activation of NF-kB.
On the other hand,  fibers can promote diarrhea, 
pain and gas aggravating the clinical state. We suggest 
that the consumption of fermentable fibers may have a 
good impact on patients‘ health.
The identification of certain SNPs associated with 
the disease allow us to detect if an individual is a car-
rier of markers of disease susceptibility. The knowledge 
of the presence of a specific genotype may suggest 
what types of  food  are linked with a well-being state. 
Further studies are therefore needed to improve nutri-
tional therapeutic approach.
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